SKYE BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.48 USD | -2.78% |
|
-4.20% | +285.29% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 14.8 | 33.59 | 294.2 | - | - |
| Enterprise Value (EV) 1 | 14.8 | 33.59 | 294.2 | 294.2 | 294.2 |
| P/E ratio | -0.41 x | -0.51 x | -11.1 x | -9.92 x | -6.78 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -12.3 x | -10.2 x | -7.37 x |
| FCF Yield | - | - | -8.12% | -9.81% | -13.6% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,654 | 12,349 | 28,068 | - | - |
| Reference price 2 | 4.050 | 2.720 | 10.48 | 10.48 | 10.48 |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -34.74 | -26.4 | -34.55 | -45.19 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -37.64 | -24.42 | -33.32 | -44.27 |
| Net income 1 | -19.48 | -37.64 | -24.42 | -33.32 | -44.27 |
| Net margin | - | - | - | - | - |
| EPS 2 | -10.00 | -5.370 | -0.9467 | -1.057 | -1.545 |
| Free Cash Flow 1 | - | - | -23.89 | -28.86 | -39.91 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -4.086 | -6.152 | -6.259 | -6.586 | -7.416 | -6.85 | -7.6 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.42 | -5.018 | -5.977 | -6.354 | -7.073 | -6.65 | -7.425 |
| Net income 1 | -24.95 | -4.42 | -5.02 | -5.977 | -6.354 | -7.073 | -6.65 | -7.425 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -3.170 | - | -0.1800 | -0.1933 | -0.2067 | -0.2300 | -0.1950 | -0.2150 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/22/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -23.9 | -28.9 | -39.9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 1.16 | 1.5 | 1.79 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.48
USD
Average target price
18.33
USD
Spread / Average Target
+74.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +285.29% | 303M | |
| +40.80% | 55.66B | |
| -8.05% | 38.98B | |
| +35.79% | 38.8B | |
| -8.98% | 27.32B | |
| +10.69% | 26.29B | |
| -16.21% | 20.25B | |
| +31.00% | 12.76B | |
| +28.51% | 12.18B | |
| -1.67% | 12.12B |
- Stock Market
- Equities
- EMBI Stock
- Financials Skye Bioscience, Inc.
